Go to menu -  Go to content -   - 

Center for Infection & Immunity of Lille


December 3th, 2018

14h00 – 14h10 : Welcome address
14h10 – 15h30 : Camille Locht, Centre of Infection and Immunity of Lille, Lille France : The History of BCG
15h30 – 16h15 : Christian Lienhardt, IRD, Montpellier, France : BCG and tuberculosis in the world today
16h15 – 17h00: Willem Hanekom, Bill and Melinda Gates Foundation, Seattle, U.S.: Efficacy of BCG against mycobacteria

17h00 – 17h30 : Coffee break

1. Genomics, Chair: Dr. Philip Supply
17h30 – 18h00 : Roland Brosch, Institut Pasteur, Paris, France: Comparative Genomics of BCG and Mycobacterium bovis
18h00 – 18h30 : Marcel Behr, McGill University Health Center, Montreal, Canada: Evolution and strain variation in BCG

Conference Dinner at Hermitage Gantois

December 4th, 2018

2. Immune responses to BCG; Chair : Dr. Nathalie Mielcarek
8h30 – 9h00 : Hazel Dockrell, London School of Hygiene and Tropcial Medicine, London, United Kingdom: Immune responses to BCG
9h00 – 9h30 : Elise Nemes, University of Cape Town, Cape Town, South Africa: Revaccination with BCG
9h30 – 10h00 : Stephen Gordon, University College Dublin, Dublin, Ireland: BCG and bovine tuberculosis

10h00 – 10h30 : Coffee break

10h30 – 12h30 : Selected Oral Presentations

12h30 – 14h00 : Lunch

3. Next generation BCG, Chair : Dr. Alain Baulard
14h00 – 14h30 : Leander Grode, Vakzine Projekt Management GmbH, Hannover, Germany: Recombinant BCG vaccine VPM1002: from concept to clinical development
14h30 – 15h00 : Luciana C. Leite, Centre de Biotecnologia, Instituto Butantan, Sao Paulo, Brazil: Recombinant BCG strains producing heterologous antigens
15h00 – 15h30 : Carlos Martin, Universidad de Zaragoza, Zaragoza, Spain: Making a new BCG from virulent Mycobacterium tuberculosis

15h30 – 17h00 : Coffee and Poster Viewing

4. Off-target effects of BCG, Chair : Dr. Ruben Hartkoorn
17h00 – 17h30 : Peter Aaby, Research Centre for Vitamins and Vaccines, Bandim Health Project, Copenhagen, Denmark: BCG vaccination and overall childhood mortality and morbidity
17h30 – 18h00 : Mihai Netea, Radboud University Medical Center, Nijmegen, The Netherlands: The induction of trained innate immunity by BCG

December 5th, 2018

5. BCG and cancer, auto-immune and inflammatory diseases; Chair : Dr. Camille Locht
9h00 - 9h45 : Donald Lamm, University of Arizona, Phoenix, Arizona, US : BCG and bladder cancer immunotherapy
9h45 – 10h15 : Delphine Lee, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, CA, United States : BCG as a therapy for inoperable cutaneous metastatic melanoma

10h15 – 10h45 : Coffee break

10h45 – 11h15 : Denise L. Faustman, Harvard Medical School, Boston, Massachusetts, United States  : BCG for treatment of long-term type 1 diabetes
11h15 – 11h45 : Marchal Gilles, Paris, France : The anti-inflammatory properties of BCG and its derivatives

11h45 – 12h15 : Closing : TBD

To top